[Impression materials--properties and technics (I)].
Explore the source record for details and available documents.
Dental Impression Materials↗
Biomedical subjects
K D Jorgensen
Publications and source records attributed to K D Jorgensen.
Effect of bevelling on the occurrence of fractures in the enamel surrounding composite resin fillings.
Three different types of cavities: (1) with a 90 degree cavo-surface angle, (2) with a bevel at the cavity margin 0-25-0-50 mm wide, and (3) with a bevel at the cavity margin 0-5-1-0 mm wide, were prepared in extracted human teeth. Fifteen cavities of all three types were filled with Adaptic. Fifteen cavities of Type 2 and of Type 3 were filled with cosmic and the same number and types of cavities with prestige. The fillings were polished 10 min after starting the mix of the composite resins. Fractures in the enamel at the cavity margins were visualized by discoloration with methylene blue. Fractures were observed around all types of cavities, but, for all types of materials, an increased bevel at the margin gave an increased number of fillings without fractures in the enamel. However, great variations in the frequency of fractures were also observed; i.e. Adaptic showing a small frequency, Cosmic a medium and Prestige a great frequency of fillings connected with fractures at the enamel margin.
Composite Resins↗
Actions of fenfluramine on glucose uptake in vitro and in vivo.
Fenfluramine stimulates the glucose uptake of the isolated hemidiaphragm from normal and streptozotocin diabetic rats in the presence of insulin. The drug does not cause an increased storage of glycogen. During hind leg perfusion of the dog fenfluramine stimulated peripheral glucose uptake. No increase in lactate or in free fatty acids release was observed during prolonged infusions of the drug. Fenfluramine caused an improvement of glucose tolerance in normal glucose-primed rats. A single dose of fenfluramine significantly lowered the blood glucose levels in streptozotocin diabetic rats and in diabetic dogs treated with insulin. Prolonged treatment with fenfluramine of streptozotocin diabetic rats had no significant effect on blood glucose levels. Additional treatment for one week of insulin dependent diabetic dogs with small non-anorexic doses of fenfluramine resulted in slightly decreased blood glucose levels. The dogs could not be maintained on fenfluramine alone (without insulin).
Animals↗
The pharmacology of a new hypoglycaemic agent N-[4-(2-(2,3-dihydrobenzo (b) furan-7-carboxamido)-ethyl)-benzenesulphonyl]-N'-cyclohexylurea (NOVO CS 476). II. Pharmacological studies on the mechanism of action.
The new sulphonylurea CS 476 does not potentiate the effect of insulin on plasma glucose levels in diabetic dogs in which an oral glucose load does not cause insulin release. In normal dogs propranolol 0.3 mg/kg intravenously inhibites the insulin release and the hypoglycaemia due to CS 476 suggesting involvement of beta-adrenergic receptors in its action on the pancreas. Pretreatment of dogs with phentolamine leads to an augmentation of the insulin response to CS 476.
Administration, Oral↗
[Porosity of composite filling materials].
The porosity of composite materials was investigated. For the 5 materials tested the values varied between 5.9 and 2.2 vol. %. The volume of porosity could be reduced markedly by a short application of pressure upon the mixed material. Pressure and time of pressure were checked separately, and it could be shown that the percentage of porosity reduction was correlated almost completely with the viscosity of the composite.
Composite Resins↗
The pharmacology of a new hypoglycaemic agent N-[4-(2-(2,3-dihydrobenzo(b)furan-m-carboxamido)-ethyl)-benzenesulphonyl]-N'-cyclohexylurea (NOVO CS 476). I. Pharmacological studies on the hypoglycaemic effect.
The new sulphonylurea CS 476 has been shown to be a potent hypoglycaemic agent. In normal fasting dogs, rabbits, rats and mice the maximal hypoglycaemia produced by intravenous administration of CS 476 was comparable on a weight basis to that produced by glibenclamide. Randomized Latin square experiments in dogs showed that 0.03 mg/kg orally of CS 476 and of glibenclamide caused the same maximal decrease of blood glucose and that CS 476 had the shorter duration of action. CS 476 had no hypoglycaemic effect in totally pancreatectomized dogs nor in streptozotocin diabetic dogs and rats. The insulin releasing activity was studied in dogs after intravenous and oral administration of equipotent doses of CS 476, tolbutamide and glibenclamide. It was found that the insulin curves after CS 476 tended to have a plateau-like maximum like those after glibenclamide although the duration of effect was shorter.
Administration, Oral↗
The pharmacology of a new hypoglycaemic agent N-[4-(2-(2,3-dihydrobenzo(b)furan-7-carboxamid o)-ethyl)-benzenesulphonyl]-N'-cyclohexlurea (NOVO CS 476). III. General pharmacological studies.
The new sulphonylurea CS 476 was tested for positive iontropic effect on the isolated cat papillary muscle. Unlike tolbutamide CS 476 had no positive inotropic effect. CS 476 had no adverse effect on blood pressure in dogs, cats and rats nor on the electrocardiogram of dogs in doses up to ten times the therapeutic dose. Unlike chlorpromide CS 476 did not potentiate the effect of exogenous antidiuretic hormone in hydrated dogs. In therapeutic concentrations the drug had no effect on smooth muscle preparations. 1,000-10,000 times therapeutic concentrations had a papaverine-like effect - similar to therapeutic concentrations of tolbutamide.
Animals↗
Recent developments in alloys for dental amalgams: their properties and proper use.
Since the development more than ten years ago of a new type of amalgam alloy that will react with mercury without forming the unfavourable gamma2 (Sn7-8Hg) phase, several new alloy brands with a similar reaction pattern have been presented. This new generation of amalgam alloy is called non-gamma2 alloy as distinct from the conventional alloys. Three of the new alloys studied contain approximately three volume percent gamma2 and should be classified as modified concentional amalgams. The non-gamma2 amalgams may be characterized in the following way: (1) instead of gamma2 they contain a reaction product of copper and tin (Cu6Sn5), the so-called eta1 phase. (2) They are significantly more resistant to corrosion than the conventional amalgams but do in time produce sufficient solid corrosion products to seal the micro-fissures between filling and cavity walls. (3) When corroding, they do not release metallic mercury, and the solid corrosion products formed and precipitated on the free surface of the fillings seem relatively little resistant to the organic acids of the plaque. (4) Most of them have relatively low creep and tensile strength, but high compressive strength. (5) Clinically the non-gamma2 amalgams are remarkable for superior marginal integrity and, seemingly, also for improved persistence of surface lustre.
Copper↗
A semi-quantitative test for mercury in air.
Explore the source record for details and available documents.
Air Pollution↗